Respiratory Syncytial Virus News and Research

RSS

A technicality could keep RSV shots from kids in need

After more than five decades of trying, the drug industry is on the verge of providing effective immunizations against the respiratory syncytial virus, which has put an estimated 90,000 U.S. infants and small children in the hospital since the start of October.

6 Feb 2023

The impact of common viral infections on blood-brain barrier function and insulin sensitivity

A new study discusses the impact of several human viruses on blood-brain barrier function and insulin sensitivity.

31 Jan 2023

Researchers explore respiratory syncytial virus infection before and during the COVID-19 pandemic

Researchers assessed the occurrence of respiratory syncytial virus (RSV) infection prior tobefore and at the time of the coronavirus disease 2019 (COVID-19) pandemic.

27 Jan 2023

FDA experts are still puzzled over who should get which covid shots and when

At a meeting to simplify the nation's covid vaccination policy, the FDA's panel of experts could agree on only one thing: Information is woefully lacking about how often different groups of Americans need to be vaccinated.

27 Jan 2023

Breathing and tilting motions of influenza glycoproteins could be exploited to better defend against flu

The potential "tripledemic" of influenza, SARS-CoV-2 and RSV (respiratory syncytial virus) infection continues to be a concern.

25 Jan 2023

Exploring the clinical impact of co-detections of other respiratory viruses in US children hospitalized for COVID-19

Researchers recently assessed the clinical impact and epidemiology of viral co-detections in children in the United States of America (USA) during the coronavirus disease 2019 (COVID-19) pandemic.

23 Jan 2023

Study reviews mechanistic data on new methods of allergy prevention and treatment

In a recent article published in Science Translational Medicine, researchers reviewed the cause and the underlying pathophysiology of allergic diseases.

23 Jan 2023

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

Researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations.

20 Jan 2023

Threshold control method could aid in future non-pharmaceutical intervention relaxation policy making

Governments around the world used a variety of techniques known as nonpharmaceutical interventions, or NPIs, to control the spread of COVID-19.

18 Jan 2023

Novel peptide suppresses the damaging lung inflammation seen in ARDS

A novel peptide designed by University of California, Irvine researchers has been found to suppress the damaging lung inflammation seen in acute respiratory distress syndrome, or ARDS.

17 Jan 2023

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

Researchers from the United States evaluated the efficacy and immunogenicity of an intranasal messenger ribonucleic acid (mRNA)-lipid nanoparticle (LNP) vaccine against SARS-CoV-2 using a hamster model.

16 Jan 2023

Study investigates the spectrum of antibody immunity across several SARS-CoV-2 variants

Researchers evaluated antibody responses to the spike proteins of the SARS-CoV-2 Wuhan-Hu-1 strain and VOCs such as the Alpha, Beta, Gamma, Delta, and Omicron.

16 Jan 2023

What are the present challenges and future considerations in developing vaccines against mucosal respiratory viruses?

In a recent review, the former director of the National Institute of Allergy and Infectious Diseases and former chief medical advisor to the president of the United States (U.S.), Dr. Fauci, and his team review the roadblocks to developing effective vaccines against viruses that infect the human respiratory mucosa and discuss strategies for next-generation vaccine development against mucosal respiratory viruses

13 Jan 2023

The 2022 U.S. RSV surge consisted of a variety of pre-existing viruses

In a recent study posted to the medRxiv* preprint server, researchers investigated whether the upsurge in respiratory syncytial virus (RSV) infections during the autumn season of 2022 occurred due to the emergence of a novel, highly transmissible RSV strain or whether multiple pre-existing RSV strains were responsible for the increase in RSV case counts during the period.

12 Jan 2023

Rethinking next generation of improved vaccines for mucosa-replicating viruses

Vaccines that provide long-lasting protection against influenza, coronaviruses and respiratory syncytial virus (RSV) have proved exceptionally difficult to develop.

11 Jan 2023

Wellcome Sanger Institute launches new initiative to better understand respiratory viruses

A new initiative to better understand respiratory viruses has been launched today (10 January 2023) by the Wellcome Sanger Institute.

10 Jan 2023

Group A streptococcal infections increased in England in 2022

In a recent study published in the journal Eurosurveillance, researchers investigated the latest increase in cases of invasive group A streptococcal (iGAS) infection among children in England below the age of 15 to understand the clinical presentations of iGAS as well as the incidence of co-infections with respiratory viruses.

9 Jan 2023